Low medication persistence for older STEMI patients

Low medication persistence for older STEMI patients

(HealthDay)—For older patients with non-ST-segment elevation myocardial infarction, evidence-based medication (EBM) persistence is similar after discharge from academic and nonacademic hospitals, according to a study published in the Nov. 15 issue of The American Journal of Cardiology.

Jennifer Rymer, M.D., M.B.A., from the Duke University Medical Center in Durham, N.C., and colleagues examined whether there is a difference in medication between patients discharged from academic versus nonacademic hospitals. Medicare pharmacy claims data were obtained for 3,184 patients with non-ST segment elevation myocardial infarction, aged older than 65 years, who were treated at 253 hospitals in 2006.

The researchers found that, at discharge, composite persistence to all EBMs was low and did not differ significantly between those discharged from academic versus nonacademic hospitals at 90 days (46 versus 45 percent; adjusted incidence rate ratio, 0.99; 95 percent confidence interval, 0.95 to 1.04) or at one year (39 versus 39 percent; adjusted incidence rate ratio, 1.02; 95 percent confidence interval, 0.98 to 1.07).

"Rates of persistence to EBMs were similar between patients with myocardial infarction >65 years old treated at academic versus nonacademic hospitals; however, persistence rates are low both early and late postdischarge, highlighting a continued need for quality improvement efforts to optimize post- management," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: American Journal of Cardiology

Copyright © 2014 HealthDay. All rights reserved.

Citation: Low medication persistence for older STEMI patients (2014, November 16) retrieved 25 April 2024 from https://medicalxpress.com/news/2014-11-medication-persistence-older-stemi-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Pharmacoinvasive STEMI strategy best for smokers, nonsmokers

 shares

Feedback to editors